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Essentials
 Platelets have the potential to internalize SARS-CoV-2
 Viral RNA may activate platelet-TLR7, leading to complement C3 secretion and netosis 
 Tissue damage, as a result of infection, can lead to thrombin and fibrin generation 
 Netosis, inflammatory cytokines, thrombin and fibrin can all contribute to thrombosis
Abstract 
For the past 150 years, platelets have been recognized as the major blood component that mediates 
hemostasis and thrombosis. In more recent years, however, we have come to appreciate that 
platelets also perform profound immune functions during infection with various pathogens. We now 
recognize that platelets can also mediate a response to various RNA viruses such as influenza and 
that many viral infections, including the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), can affect platelet count. Thrombocytopenia and increased coagulation have been 
independently associated with increased mortality. This article provides a perspective on the 
potential roles of platelets during COVID-19. 
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COVID-19 has already caused severe health and economic burdens worldwide and, as of 
May 15th, has claimed 60, 300 total deaths in the United States (1). COVID-19 presents with various 
symptoms which include increased inflammatory cytokines, dysregulated coagulation parameters, 
increased D-dimer, increased microthrombi and reduced platelet count (2). In COVID-19 patients, 
disseminated intravascular coagulation (DIC) and reduced platelet count are associated with poor 
prognosis and increased risk of mortality (2-4). These clinical observations suggest that platelets 
may serve important functions during COVID-19 progression. In order to understand how the 
incidence of microthrombosis and reduced platelet count may occur during SARS-CoV-2 infection, it 
is necessary to look at the potential active versus reactive roles of platelets during progression of 
SARS-CoV-2 infection. 
The first stage of infection involves viral replication in epithelial cells of the respiratory tract. 
SARS-CoV-2 is a single-stranded RNA virus classified as β-coronavirus. It is an upper respiratory 
virus that, similarly to influenza, becomes problematic when it reaches the lower lung epithelial cells. 
These cells comprise the lining of the alveolar sacs and are located in very close proximity to the 
capillary endothelial cells. This proximity established by both cell types is instrumental to gas 
exchange. In the capillary, platelets are essential in mediating endothelial integrity by performing 
their hemostatic function (5). During infection with respiratory viruses, however, the integrity of 
infected epithelial and endothelial cells becomes compromised, leading to increased permeability 
that may allow virus to crossover into the circulation. Limited presence of SARS-CoV2 RNA in blood 
has been reported in some patients (6). Of note, viral RNA tested by qPCR does not indicate 
presence of infectious virus in blood. qPCR can amplify fragmented RNA while plaque assays are 
appropriate for determination of infectious virus.
Due to their abundance, platelets may be the first blood component to internalize viral 
particles and induce a response once the pathogen reaches circulation. For example, although 
viremia (infectious virus in blood) is considered rare, platelets from influenza infected patients have 
been found to contain influenza particles (7).  Influenza, similarly to SARS-CoV-2, is a single 
stranded RNA respiratory virus that can infect the alveolar epithelial cells. In human platelets, the 
initial response to single-stranded viral RNA (vRNA) is mediated predominantly by toll-like receptor 7 
(TLR7) (7, 8). TLR7 is located in the endo-lysosomes of platelets, and requires both internalization of 
the viral particle and the acidic pH of the endo-lysosome for proper activation and signaling (7, 8). 
During influenza infection, one platelet can internalize many viral particles which colocalize with A
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TLR7 in the lysosomes (7). Activation of TLR7 leads to α-granule release in an AKT and p38-
dependent manner and consequently leads to interaction of platelets with neutrophils via P-selectin 
and CD40L (8). In addition, platelet-TLR7 leads to complement C3 release which pushes neutrophils 
to release their DNA in the process of netosis (7). C3-mediated netosis does not require the 
attachment of neutrophils to the vascular bed and netting neutrophils can circulate in blood (7). 
Neutrophil extracellular traps (NETs) capture and protect from viral challenge (9), but are also highly 
prothrombotic and, when dysregulated, may induce intravascular coagulation. Thrombin generated 
from coagulation in turn can activate C3 and, consequently, the entire proinflammatory complement 
cascade (10). In support of intravascular DNA release from neutrophils and potential applicability to 
this mechanism, sera from COVID-19 patients contains highly specific markers for netosis (11).
Netosis, at the site of infection is necessary for protection against viral challenge (9). 
Conversely, uncontrolled netosis can cause severe cell and organ damage suggesting that limiting 
the levels of netosis is crucial for vascular maintenance. Interestingly, in addition to C3, influenza-
exposed platelets also secrete GM-CSF in a neutrophil-dependent manner (7). GM-CSF in turn 
controls the levels of DNA released from neutrophils (7). Thus, platelets exhibit two major functions 
when single-stranded vRNA is recognized by TLR7: they initiate netosis, which is necessary to 
remove virus from the circulation, and they modulate the level of DNA release (Figure 1). This 
process likely occurs in some form at the start of infection before the host becomes symptomatic. As 
infection progresses, this C3-NET-GM-CSF response can become dysregulated and amplified due to 
increased levels of inflammatory cytokines, tissue damage, and from direct neutrophil activation by 
the virus.  Increased C3 and GM-CSF have been reported in COVID-19 patients (12, 13); but the 
contribution of platelets is yet to be established. 
The plausibility of the TLR7-C3-netosis mechanism is dependent on internalization of SARS-
CoV-2. The surface receptor that recognizes SARS-CoV-2 is ACE2 and binding of the two initiates 
internalization by receptor-mediated endocytosis. It is unclear if platelets express the ACE2 protein 
on their surface and whether this expression changes during infection. ACE2 mRNA, however, is not 
detected by sequencing of human platelets (14, 15).  ssRNA viruses such as influenza can also be 
internalized by other mechanisms that are independent of receptor recognition. Processes such as 
micropinocytosis leading to uptake of large-sized cargo through endocytic vesicles, or phagocytosis 
of fragments from apoptotic influenza-infected cells, have been both described as a non-specific 
point of viral entry into other cell types (16, 17). Other mechanisms of internalization specific to A
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platelets may also be involved. It is well accepted that platelets can actively acquire RNA from 
endothelial cell and internalize circulating vesicles, debris, mitochondria, pollen particles, etc (18).  
The exact mechanisms of internalization by platelets are not clear, but due to their abundance, lack 
of a nucleus and open canalicular system, the likelihood of platelets sticking to SARS-CoV-2 
particles is very high. A better understanding of viral entry into platelets could be instrumental in 
targeting platelet function during COVID-19.
As previously mentioned, platelets are important in maintaining vascular homeostasis and 
endothelial integrity in the alveolar capillaries. As infection progresses, shedding of epithelial cells is 
also observed. In addition to the profound cytokine storm that occurs, some SARS-CoV-2 viral 
particles can reach and infect the endothelial cells that are highly ACE2 positive (19). Infected 
endothelium, particularly in the small vessels, where blood flow is much slower than in the big 
arteries, can lead to thrombosis (20). Thus, multiple mechanisms may be contributing to thrombosis 
at this stage of COVID-19. Direct infection of endothelial cells may lead to damage of the endothelial 
lining by apoptosis or pyroptosis. As a result, exposed subendothelial matrix could trigger platelets to 
enter their hemostatic mode, aggregate and attempt to repair the damage (18). Even if infection of 
the endothelium does not occur, the vast tissue inflammation and propensity for netosis described in 
COVID-19 patients (21, 22) can lead to compromised endothelial function and increased expression 
of adhesion molecules (20). As more endothelial cells become infected, more platelets will aggregate 
and form microthrombi in the vessels. The size of thrombus formation and, consequently, thrombus 
dissolution is limited and controlled by healthy endothelium that would generally release 
prostaglandins, NO and increase levels of adenosine (20). In that sense, if the endothelium is 
compromised due to direct infection and/or inflammation, it will be unable to limit thrombus formation. 
Additionally, the damage caused by inflammation and netosis during infection can also lead to tissue 
factor release. Tissue factor would further amplify the thrombotic response of platelets by generating 
thrombin and fibrin fibers. Lack of functional endothelium and tissue factor can further contribute to 
the increased propensity for thrombosis in small vessels presenting as pulmonary embolism and 
deep vein thrombosis despite anticoagulation treatment (23).
Inflammatory cytokines underlying the etiology of COVID-19 can directly affect platelet 
function and further contribute to their thrombotic propensity. The relevance of acute inflammation is 
even greater when considered in addition to the chronic inflammation underlying obesity and aging 
(Figure 1).  IL6 is increased with obesity and TNFα is increased with aging in humans. IL6, IL1b and A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
TNFα are also elevated in the plasma of COVID-19 patients (12, 24). IL6 or IL1b can lead to platelet 
hyper-activation and spreading (25), and both of these cytokines can augment agonist-induced 
platelet aggregation (26, 27).  Exposure of whole blood to IL6 and IL1b may lead to increased 
hypercoagulability and pathological changes that affect not only platelets but also erythrocytes (25). 
TNFα, on the other hand, promotes the development of age-related platelet hyperactivity and 
consequently increases thrombosis risk (28). Overall, these inflammatory cytokines can amplify the 
thrombotic response of platelets and lead to further activation and platelet exhaustion.
As infection progresses and the adaptive immune response begins, there is a possibility that 
platelets can become further activated by antibodies to the virus similarly to influenza (29).  In this 
case, platelet-FcγRIIa recognizes IgG antibodies that have scaffolded viral particles and 
subsequently lead to platelet activation through thrombin generation (29). 
In summary, over the course of SARS-CoV-2 infection, platelets may perform various 
functions in concert with neutrophils, erythrocytes, and endothelial cells that can increase the 
cumulative incidence of thrombosis. At the beginning of infection, platelets may actively induce 
netosis, which can become dysregulated as infection progresses.  Additionally, platelets can react to 
inflamed and infected endothelium, inflammatory cytokines, and antibody level changes which can all 
contribute to amplification of their thrombotic function. Keeping in mind that thrombocytopenia and 
microthrombosis are difficult to resolve simultaneously, perhaps targeting inflammatory cytokine 
signaling and netosis during COVID-19 may be a better approach than providing antiplatelet drugs.  
Further investigations are necessary to examine the factual role of platelets in response to SARS-
CoV-2. 
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Figure Legend:
Figure 1: Potential roles of platelets during COVID-19. As infection progresses and the virus 
infects the epithelial cells of the alveoli, some of the viral particles have the potential to crossover into 
the circulation. Once in the circulation, platelets can internalize the virus and the viral ssRNA can 
activate TLR7. Platelet-TLR7 activation leads to release of Complement C3 (C3) from their alpha 
granules. C3 leads to netosis and the released neutrophilic DNA captures any virus that may have 
been missed by platelets. Platelets may also control the magnitude of netosis by releasing GM-CSF 
as a result of a (unknown) signal that comes from neutrophils. As infection progresses, other cells 
also contribute to the C3 pool and further increase netosis. At this stage, platelets may no longer be 
able to regulate the level of netosis by secreting GM-CSF due to their exhaustion or reduction in 
number. Additionally, infection-damaged tissue will also lead to tissue factor (TF) release, which will 
generate thrombin (FIIa) through the intrinsic coagulation cascade. Thrombin, in turn, can increase 
fibrin generation (from fibrinogen), direct platelet aggregation, and C3 activation. Inflammatory 
cytokines such as IL1b or IL6 can further contribute to platelet-aggregation. All of these mechanisms 
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would be of particular relevance in the small vessels where flow velocity is reduced and the 
protective role of the endothelial lining is compromised due to the direct infection.  
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